Targeted Oncology1h
The Targeted Pulse: Sniffing out the Latest From ASCO GI 2025 and Fresh FDA Activity
Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for ...
FDA approves Datroway for HR-positive, HER2-negative breast cancer
The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...
The American Journal of Managed Care1d
FDA Approves First HER2-Ultralow Companion Diagnostic, Expanding Treatment Eligibility
Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...
Healthcare experts hail Budget 2025’s push for daycare cancer centers, drug cost relief
Healthcare experts lauded the announcement by Finance Minister Nirmala Sitharaman to setting up daycare cancer centres, ...
New Atlas2d
"Kick and kill": HIV cure could be hiding in FDA-approved drug
HIV has become a more manageable condition in recent years, but a full cure remains elusive. Now, scientists have found ...
I'm a cancer doctor - these are the 6 biggest myths patients need to be aware of
Dr Liz O'Riordan's brilliant new book aims to challenge misinformation about cancer. In an exclusive extract, she tackles ...
Exclusive: Cowboys QB Dak Prescott supports effort to get cancer test covered by Medicare
Bill to pay for multi-cancer early detection screening test has bipartisan support, but just ran out of time last session.
Healio4d
FDA expands Enhertu approval for breast cancer
The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...
Could the FDA's recently approved Pap smear alternative reduce racial disparities in cervical cancer deaths?
Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical ...
Targeted Oncology5d
FDA Approves T-DXd in HR+, HER2-Low/Ultralow Breast Cancer
The FDA approved trastuzumab deruxtecan for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast ...
FiercePharma4d
AZ, Daiichi's Enhertu nabs 7th FDA nod, including in 'HER2-ultralow' use, in breast cancer first
Just 11 days after AstraZeneca and Daiichi Sankyo gained FDA approval | The FDA has cleared AstraZeneca and Daiichi Sankyo's ...
Cure Today5d
FDA Approves Enhertu for HER2-Low and -Ultralow Breast Cancer
The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer with disease progression after endocrine therapy.